Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG a score in ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label ...

Imaavy’s approval is based on data from the pivotal Vivacity-MG3 trial. It demonstrated that the antibody with standard of care (SOC) significantly improved disease control over 24 weeks against ...

1 The approval of the FcRn-blocking monoclonal antibody, which works by reducing immunoglobulin G (IgG), was supported by data from the ongoing Vivacity-MG3 study. Nipocalimab joins a roster of ...

The FDA's decision was based on the phase III Vivacity-MG3 study and its ongoing open-label extension. The primary endpoint in Vivacity-MG3 was the change in Myasthenia Gravis Activities of Daily ...